What is Neuroblastoma?
Neuroblastoma is a rare cancer that develops from immature nerve cells called neuroblasts, most commonly occurring in the adrenal glands, chest, abdomen, or pelvis. This aggressive childhood cancer primarily affects infants and young children, with about 90% of cases diagnosed before age 5. Neuroblastoma accounts for approximately 6-10% of all childhood cancers and affects roughly 1 in 7,000 children. While challenging to diagnose and treat, advances in targeted therapies and immunotherapy have significantly improved outcomes for many patients.
Key statistics
| Prevalence | ~1 in 7,000 children |
| Annual incidence | 10.2 cases per million children under 15 |
| Age of onset | 90% diagnosed before age 5; median age 17 months |
| 5-year survival rate | 80% overall; varies from 95% (low-risk) to 50% (high-risk) |
Symptoms
Common symptoms: Abdominal mass or swelling, bone pain, fever, weight loss, fatigue, irritability, loss of appetite, difficulty breathing, raccoon eyes (bruising around the eyes), opsoclonus-myoclonus syndrome (dancing eyes and jerky movements).
Early symptoms often depend on the tumor’s location. Abdominal neuroblastomas, the most common type, typically present as a firm, non-tender mass that parents may notice during bathing or dressing. Children may experience discomfort, constipation, or difficulty urinating due to pressure from the growing tumor.
Neurological symptoms can be particularly distinctive. Opsoclonus-myoclonus syndrome affects 2-3% of patients and involves rapid, chaotic eye movements combined with sudden muscle jerks. This autoimmune response can occur even when the tumor is small and may persist after successful cancer treatment.
Catecholamine excess from adrenal involvement can cause high blood pressure, rapid heartbeat, sweating, and flushing. When neuroblastoma spreads to bones, children may develop limping, refusal to walk, or complaints of leg or back pain. “Raccoon eyes” – distinctive bruising around both eyes – indicates spread to facial bones and requires immediate medical attention.
Advanced disease may cause systemic symptoms including persistent fever, significant weight loss, and pallor from anemia. Some children develop Horner’s syndrome (drooping eyelid, constricted pupil) when chest tumors affect nearby nerves.
Causes and risk factors
Neuroblastoma is mostly sporadic, meaning it occurs randomly without a clear inherited cause. Approximately 1-2% of cases are hereditary, typically involving mutations in the ALK gene or PHOX2B gene. These familial cases often present at younger ages and may involve multiple tumor sites.
Several genetic factors influence neuroblastoma development and behavior. MYCN gene amplification occurs in about 20% of cases and indicates more aggressive disease. Chromosomal abnormalities, including deletions of chromosome 1p and 11q, also affect prognosis.
Known risk factors are limited. Children with certain genetic syndromes, including Beckwith-Wiedemann syndrome and neurofibromatosis type 1, have slightly increased risk. Some studies suggest potential associations with parental occupational exposures or maternal factors during pregnancy, but evidence remains inconclusive.
Unlike many adult cancers, neuroblastoma shows little connection to environmental exposures, lifestyle factors, or infections. The young age of onset suggests that initiating genetic changes likely occur during fetal development.
Prevention
No proven prevention strategies exist for neuroblastoma since most cases are sporadic and occur during early childhood development. Unlike some other cancers, neuroblastoma is not associated with modifiable lifestyle factors or environmental exposures that could be avoided.
For families with hereditary neuroblastoma (1-2% of cases), genetic counseling is essential. Genetic testing can identify mutations in ALK, PHOX2B, or other associated genes in family members. Parents with these mutations have a 50% chance of passing the gene change to each child.
Prenatal genetic testing may be available for families with known mutations, though decisions about testing require careful discussion with genetic counselors about the complexity of inheritance patterns and variable disease severity.
Some countries previously implemented neuroblastoma screening programs for infants, but these were discontinued as studies showed they detected many tumors that would have spontaneously regressed without treatment, potentially subjecting children to unnecessary procedures.
Complications
Without treatment, neuroblastoma typically progresses rapidly and can spread throughout the body. Local tumor growth may compress vital organs, causing respiratory distress, kidney dysfunction, or spinal cord compression with paralysis risk.
Metastatic spread commonly affects bones, bone marrow, liver, and lymph nodes. Bone marrow involvement can cause severe anemia, bleeding problems, and increased infection risk. Liver metastases may cause abdominal distension and organ dysfunction.
Long-term complications can result from both the cancer and its treatment. Survivors may experience hearing loss, kidney problems, growth delays, learning difficulties, and increased risk of secondary cancers. High-risk patients receiving intensive treatment face greater risks of late effects.
Opsoclonus-myoclonus syndrome, while indicating a good cancer prognosis, can cause lasting neurological problems including developmental delays, behavioral issues, and movement disorders that may require ongoing therapy.
Catecholamine-secreting tumors can cause dangerous hypertensive crises if not managed carefully, particularly during surgery or other stressful procedures.
Diagnosis
Neuroblastoma diagnosis requires combining clinical presentation, imaging studies, laboratory tests, and tissue confirmation. Initial evaluation includes complete blood count, comprehensive metabolic panel, and lactate dehydrogenase levels.
Urine catecholamine measurements are crucial, as 85-90% of neuroblastomas produce elevated vanillylmandelic acid (VMA) and homovanillic acid (HVA). These 24-hour urine collections or spot urine ratios help confirm diagnosis and monitor treatment response.
Imaging begins with ultrasound for abdominal masses, followed by cross-sectional imaging. CT or MRI defines tumor extent and evaluates for metastases. MIBG (metaiodobenzylguanidine) scintigraphy is particularly valuable, as 90% of neuroblastomas concentrate this radiotracer, helping identify primary and metastatic sites.
Tissue diagnosis requires biopsy or complete tumor removal when feasible. Pathological examination includes histological classification, MYCN amplification status, and other genetic markers that determine risk stratification and treatment planning.
Bone marrow examination through bilateral aspirates and biopsies evaluates for metastatic involvement. Genetic testing of tumor tissue identifies chromosomal abnormalities and molecular markers essential for prognosis and treatment selection.
Treatment
Neuroblastoma treatment is highly individualized based on risk stratification incorporating age, stage, histology, and genetic features. Low-risk cases may require only observation or surgery, while high-risk disease demands multimodal therapy.
Surgery aims for complete tumor removal when feasible, though extensive procedures may be delayed until after chemotherapy shrinks the tumor. Surgical expertise is crucial given the complexity of anatomical locations.
Chemotherapy regimens typically include combinations of cyclophosphamide, doxorubicin, etoposide, carboplatin, and ifosfamide. High-risk patients receive intensive induction chemotherapy followed by high-dose chemotherapy with stem cell rescue.
Radiation therapy targets the primary tumor site and sometimes metastatic locations, particularly in high-risk cases or when complete surgical removal isn’t possible.
Immunotherapy has transformed high-risk neuroblastoma treatment. Dinutuximab is an anti-GD2 monoclonal antibody approved for high-risk neuroblastoma maintenance therapy. Dinutuximab beta provides an alternative anti-GD2 therapy option.
Targeted therapies are emerging for specific genetic subtypes. ALK inhibitors show promise for tumors with ALK mutations, while other agents target different molecular pathways.
Prognosis
Neuroblastoma prognosis varies dramatically based on multiple factors. Overall 5-year survival rates approach 80%, but outcomes range from over 95% for low-risk disease to approximately 50% for high-risk cases.
Age at diagnosis significantly influences prognosis. Infants under 18 months generally have better outcomes, partly due to the potential for spontaneous tumor regression in very young children. Paradoxically, some advanced-stage disease in infants carries a better prognosis than similar-stage disease in older children.
MYCN amplification strongly predicts poor prognosis regardless of other factors. Conversely, favorable histology, diploid DNA content, and certain chromosomal patterns indicate better outcomes.
Treatment advances have substantially improved survival rates over recent decades. High-risk patients who achieve remission with modern protocols have significantly better long-term survival than historical cohorts, though cure rates remain challenging for the highest-risk subgroups.
Quality of survival has also improved with better supportive care and recognition of late effects, allowing many survivors to lead productive, healthy lives despite treatment intensity.
Quality of life
Children with neuroblastoma and their families face significant challenges during treatment and recovery. Treatment often requires prolonged hospitalization, limiting normal childhood activities and school attendance. Educational support and tutoring help maintain academic progress.
Physical therapy and occupational therapy address treatment-related complications including hearing loss, motor delays, and strength deficits. Nutritional support becomes crucial during intensive chemotherapy when appetite and eating difficulties are common.
Mental health support benefits both patients and families navigating this stressful journey. Child life specialists, counselors, and support groups provide coping strategies and emotional assistance.
Long-term survivors require ongoing monitoring for late effects. Regular exercise appropriate to individual capabilities helps maintain physical fitness and bone health. Hearing protection becomes important for those with treatment-related hearing loss.
Many survivors successfully return to normal activities including sports, school, and eventual careers. Support networks help families adapt to the “new normal” following treatment completion while maintaining hope and resilience.
Pregnancy and fertility
Neuroblastoma primarily affects young children, making pregnancy considerations rare. However, treatment can impact future fertility in both male and female patients.
Chemotherapy and radiation may affect developing reproductive organs, potentially causing infertility or early menopause in female survivors and reduced sperm production in males. Fertility preservation options should be discussed before treatment when age-appropriate.
For adult survivors planning pregnancy, genetic counseling is recommended, particularly for those with hereditary neuroblastoma. Prenatal monitoring may be advised, though most neuroblastoma is sporadic.
Female survivors who become pregnant require specialized obstetric care due to potential treatment-related complications affecting kidney function, heart health, or other organ systems.
Children
Since neuroblastoma predominantly affects children, pediatric considerations are central to all aspects of care. Age-appropriate communication about diagnosis and treatment helps children understand their situation while maintaining hope.
Developmental considerations influence treatment planning and supportive care. Infants require specialized nursing care and feeding support. Toddlers and preschoolers benefit from play therapy and familiar comfort items during hospitalization.
School-age children need educational accommodations and peer support. Treatment may occur during crucial developmental periods, requiring attention to cognitive, social, and emotional development.
Family dynamics often revolve around the affected child’s care, potentially impacting siblings who may feel neglected or worried. Sibling support programs and counseling help maintain family stability.
Long-term follow-up addresses growth, development, learning abilities, and psychosocial adjustment as survivors transition through childhood into adolescence and adulthood.
When to see a doctor
Immediate medical attention is needed for: sudden onset of “raccoon eyes” bruising, severe abdominal pain, difficulty breathing, inability to walk or leg weakness, persistent high fever, or rapid onset of jerky movements with chaotic eye movements.
Routine pediatric evaluation should address: persistent abdominal swelling or masses noticed by parents, unexplained bone pain lasting more than a week, significant weight loss without obvious cause, or persistent fatigue and irritability.
Since early symptoms can be subtle and non-specific, parents should trust their instincts when children seem unwell in ways that don’t match typical childhood illnesses. Healthcare providers should maintain high suspicion for neuroblastoma in children presenting with concerning symptoms, particularly given the importance of early diagnosis.
Regional context
Limited specific data exists regarding neuroblastoma prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean areas. The condition likely follows similar patterns to other populations, but genetic factors and healthcare access may influence outcomes.
Regional pediatric oncology centers and international collaborations help ensure optimal care delivery. Telemedicine and consultation networks can connect local providers with specialized neuroblastoma experts.
Global Medical Journal welcomes contributions from healthcare providers and researchers in these regions to better understand neuroblastoma patterns, challenges, and outcomes in diverse populations.
Research and clinical trials
Neuroblastoma research focuses on understanding tumor biology, developing targeted therapies, and improving treatment strategies. Current investigations include novel immunotherapies, CAR-T cell treatments, and precision medicine approaches based on tumor genetics.
Recent breakthroughs include the success of anti-GD2 immunotherapy and identification of actionable genetic targets. Ongoing studies evaluate combination therapies, reduced-intensity treatments for favorable-risk patients, and innovative approaches for refractory disease.
Families can find current clinical trials at ClinicalTrials.gov, though participation decisions should involve detailed discussions with the medical team about potential benefits and risks.
International collaborative groups like the Children’s Oncology Group (COG) and International Society of Paediatric Oncology (SIOP) coordinate research efforts to accelerate progress and ensure consistent treatment standards worldwide.
Frequently asked questions
Is neuroblastoma hereditary?
Most neuroblastoma cases (98-99%) are sporadic and not inherited. Only 1-2% of cases are hereditary, usually involving ALK or PHOX2B gene mutations. Genetic counseling is recommended for families with multiple affected members.
Can neuroblastoma be cured?
Yes, many children with neuroblastoma can be cured. Overall cure rates approach 80%, with over 95% cure rates for low-risk disease. High-risk cases are more challenging but still potentially curable with intensive treatment.
Why does neuroblastoma mainly affect young children?
Neuroblastoma develops from primitive nerve cells that normally mature during fetal development. When these cells fail to mature properly, they can become cancerous. This process typically occurs very early in life, explaining why most cases appear in infancy and early childhood.
What are the long-term effects of neuroblastoma treatment?
Treatment effects vary by intensity but may include hearing loss, kidney problems, growth delays, learning difficulties, fertility issues, and increased risk of secondary cancers. Regular follow-up care helps monitor and manage these potential complications.
How is neuroblastoma different from other childhood cancers?
Neuroblastoma is unique in its potential for spontaneous regression in infants, its production of catecholamines, and its response to immunotherapy targeting the GD2 antigen. The wide range of behaviors from regression to aggressive spread makes it particularly complex to treat.
Support and resources
International Organizations:
- Childhood Cancer International – childhoodcancerinternational.org
- International Society of Paediatric Oncology (SIOP) – siop-online.org
- National Organization for Rare Disorders (NORD) – rarediseases.org
- Orphanet – orpha.net
- EURORDIS Rare Diseases Europe – eurordis.org
Neuroblastoma-Specific Organizations:
- Neuroblastoma Children’s Cancer Alliance – neuroblastomacancer.org
- Band of Parents –
Cite this page
GMJ News Desk. “Neuroblastoma.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/neuroblastoma/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?